HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Annual Report With Monthly Production Totals Added To OTC Monograph Drug Firms' To-Do List

Executive Summary

Firms making drugs available in US without pre-market approval, including homeopathics, got another annual reporting requirement under CARES Act.  “It's going to be a bit of a sea change for the industry, and they're going to need to be prepared for it,” says attorney Ann Begley.

You may also be interested in...



Drug Firms Have More Time For First Annual Report On Production Volumes US Is Requiring

FDA announces day before due date that as it continues considering comments to a draft guidance on the requirement it published in October, the “document is not a binding document” and “the recommended … reporting date for 2020 data is not a requirement.”

US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD

Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.

US Courts Reject Reinstating FDA's Homeopathic Drug Policy As Challenge To Change Proceeds

Decisions in US Circuit and District courts for District of Columba are on complaint by Rx drug firm MediNatura, but should resonate for OTC homeopathic firms as well as all businesses across the sector. MediNatura appealed district ruling rejecting request for injunction against FDA’s withdrawal of 1988 homeopathic CPG.

Related Content

Topics

UsernamePublicRestriction

Register

RS151910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel